ArticleGenetics in medicine : official journal of the American College of Medical Genetics2011
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- The full spectrum of ethical issues in dementia research: findings of a systematic qualitative review.BMC medical ethics · 2021Pooled it
- Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.Journal of neural transmission (Vienna, Austria : 1996) · 2019Pooled it
- Using ApoE Genotyping to Promote Healthy Lifestyles in Finland - Psychological Impacts: Randomized Controlled Trial.Journal of genetic counseling · 2015Trial
- A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Trial
- Parental Perceptions of Benefits and Risks Concerning Mental Health Biomarker Testing for Adolescents.Community mental health journal · 2026Article
- Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma.Psychology and aging · 2026Article
- Barriers and facilitators to recruitment, engagement, and retention of underrepresented populations in dementia prevention research: a scoping review.The journal of prevention of Alzheimer's disease · 2026Article
- Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study.Alzheimer's research & therapy · 2024Article
- Attitudes of Family Members and Caregivers Regarding Alzheimer's Disease Pre-Symptomatic Screening.Journal of Alzheimer's disease reports · 2024Article
- Validation of the "Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening" (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening.Journal of Alzheimer's disease : JAD · 2024Article
- Public perspective on medications to delay Alzheimer's disease symptoms.Journal of genetic counseling · 2023Article
- Return of Results in Genomic Research Using Large-Scale or Whole Genome Sequencing: Toward a New Normal.Annual review of genomics and human genetics · 2023Review
- Patient values and preferences regarding prognostic counseling in isolated REM sleep behavior disorder.Sleep · 2023Article
- Article
- Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).Journal of Alzheimer's disease : JAD · 2021Article
- Implementation of personalized medicine in Central-Eastern Europe: pitfalls and potentials based on citizen's attitude.The EPMA journal · 2018Article
- Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.Neuroethics · 2017Article
- The impact of personal genomics on risk perceptions and medical decision-making.Nature biotechnology · 2016Article
- Perceived ambiguity as a barrier to intentions to learn genome sequencing results.Journal of behavioral medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
purposePerceptions about the pros and cons of genetic susceptibility testing are among the best predictors of test utilization. How actual testing changes such perceptions has yet to be examined.
methodsIn a clinical trial, first-degree relatives of patients with Alzheimer disease received genetic risk assessments for Alzheimer disease including APOE disclosure. Participants rated 11 possible benefits associated with genetic testing (pros) and 10 risks or limitations (cons) before genetic risk disclosure and again 12 months afterward.
resultsPros were rated higher than cons at baseline (3.53 vs. 1.83, P < 0.001) and at 12 months after risk disclosure (3.33 vs. 1.88, P < 0.001). Ratings of pros decreased during the 12-month period (3.33 vs. 3.53, P < 0.001). Ratings of cons did not change (1.88 vs. 1.83, P = 0.199) except for a three-item discrimination subscale which increased (2.07 vs. 1.92, P = 0.012). Among specific pros and cons, three items related to prevention and treatment changed the most.
conclusionThe process of APOE genetic risk assessment for Alzheimer disease sensitizes some to its limitations and the risks of discrimination; however, 1-year after disclosure, test recipients still consider the pros to strongly outweigh the cons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.